Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report) Director G Bradley Cole sold 3,673 shares of the stock in a transaction on Wednesday, July 29th. The stock was sold at an average price of $81.43, for a total transaction of $299,092.39. Following the completion of the sale, the director owned 11,672 shares in the company, valued at $950,450.96. The trade was a 23.94% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Kiniksa Pharmaceuticals International Price Performance
Shares of Kiniksa Pharmaceuticals International stock opened at $74.34 on Friday. The firm has a fifty day moving average price of $59.04 and a 200 day moving average price of $51.13. Kiniksa Pharmaceuticals International, plc has a 1 year low of $29.90 and a 1 year high of $82.94. The stock has a market cap of $5.72 billion, a PE ratio of 76.64 and a beta of 0.07.
Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last posted its earnings results on Tuesday, July 28th. The company reported $0.30 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.30. Kiniksa Pharmaceuticals International had a net margin of 9.59% and a return on equity of 13.65%. The company had revenue of $243.60 million during the quarter, compared to the consensus estimate of $226.49 million. As a group, equities analysts expect that Kiniksa Pharmaceuticals International, plc will post 1.38 EPS for the current year.
Hedge Funds Weigh In On Kiniksa Pharmaceuticals International
A number of large investors have recently bought and sold shares of the business. Vanguard Group Inc. grew its holdings in Kiniksa Pharmaceuticals International by 1.6% in the 4th quarter. Vanguard Group Inc. now owns 3,112,937 shares of the company's stock valued at $128,409,000 after buying an additional 49,802 shares in the last quarter. UBS Group AG raised its holdings in shares of Kiniksa Pharmaceuticals International by 56.4% during the 4th quarter. UBS Group AG now owns 77,916 shares of the company's stock worth $3,214,000 after acquiring an additional 28,099 shares during the period. Aberdeen Group plc boosted its position in shares of Kiniksa Pharmaceuticals International by 152.4% during the 4th quarter. Aberdeen Group plc now owns 400,598 shares of the company's stock valued at $16,525,000 after acquiring an additional 241,876 shares during the last quarter. Inspire Investing LLC purchased a new stake in shares of Kiniksa Pharmaceuticals International in the first quarter valued at about $1,698,000. Finally, BNP Paribas Financial Markets grew its holdings in shares of Kiniksa Pharmaceuticals International by 27.3% in the fourth quarter. BNP Paribas Financial Markets now owns 831,777 shares of the company's stock valued at $34,311,000 after purchasing an additional 178,366 shares during the period. Institutional investors and hedge funds own 53.95% of the company's stock.
Analyst Upgrades and Downgrades
KNSA has been the subject of several analyst reports. Wells Fargo & Company boosted their price objective on Kiniksa Pharmaceuticals International from $57.00 to $74.00 and gave the company an "overweight" rating in a report on Monday, July 13th. Zacks Research raised Kiniksa Pharmaceuticals International from a "hold" rating to a "strong-buy" rating in a report on Wednesday, June 17th. Canaccord Genuity Group lifted their price target on Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the company a "buy" rating in a research report on Wednesday. Wedbush boosted their price target on Kiniksa Pharmaceuticals International from $72.00 to $99.00 and gave the company an "outperform" rating in a report on Wednesday. Finally, Jefferies Financial Group upped their price objective on Kiniksa Pharmaceuticals International from $58.00 to $71.00 and gave the stock a "buy" rating in a research report on Tuesday, April 28th. One research analyst has rated the stock with a Strong Buy rating and nine have issued a Buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average price target of $87.38.
Check Out Our Latest Report on KNSA
Kiniksa Pharmaceuticals International Company Profile
(
Get Free Report)
Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company's core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.
The company's lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still's disease and Schnitzler syndrome.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
